Business Context and Reporting Period
Actinium Pharmaceuticals, Inc. filed a Form 8-K Current Report on July 3, 2017. The filing discloses the entry into a material definitive agreement regarding the sale of the company's common stock.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the commission fee structure for the new sales agreement, set at 3.0% of gross proceeds from stock sales.
Material Changes
On July 3, 2017, the Company amended its existing At-the-Market Issuance Sales Agreement (originally dated March 24, 2014). The material change involves adding FBR Capital Markets & Co. and JonesTrading Institutional Services LLC as additional agents alongside the original agent, MLV & Co. LLC.
Outlook, Risks, and Management Commentary
- Agreement Terms: The agents will use commercially reasonable efforts to sell common stock on the NYSE MKT LLC or other markets based on Company instructions.
- Compensation: The Company will pay agents 3.0% of gross proceeds in cash upon the sale of stock.
- Documentation: A copy of the Amended Agreement is included as an exhibit to the Form 10-Q for the quarter ending June 30, 2017.
Investor Verification Checklist
- Verify the total amount of common stock sold under the Amended Agreement in subsequent filings.
- Review the Form 10-Q for the quarter ended June 30, 2017, for the full text of the Amended Agreement.
- Monitor cash flow impacts from the 3.0% commission fees on future equity raises.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.